Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of three injectable drugs, indicating progress in its oncology pipeline [1] Group 1: Drug Approvals - The company's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd. have received clinical trial approval for SHR-1826, Adebali monoclonal antibody injection, and Bevacizumab injection [1] - SHR-1826 is an antibody-drug conjugate targeting c-MET, designed to selectively bind to tumor cell surface antigens and induce cell death [1] - Adebali monoclonal antibody injection, a humanized anti-PD-L1 monoclonal antibody, aims to block the PD-1/PD-L1 pathway, reactivating the immune system's anti-tumor activity [1] - Adebali monoclonal antibody injection (brand name: Ailili) was approved for market in March 2023 for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [1] - Bevacizumab is a humanized anti-VEGF monoclonal antibody, co-developed by Genentech and a Chinese pharmaceutical company, and has been marketed globally since its approval in the U.S. in 2004 [1] - The company's Bevacizumab injection was approved for market in June 2021, with multiple formulations currently available in China [1]

Core Viewpoint - Heng Rui Medicine (600276) has announced a 2025 A-share employee stock ownership plan aimed at establishing a profit-sharing mechanism among the company, shareholders, and employees to enhance employee motivation, creativity, cohesion, and overall competitiveness, thereby promoting the company's long-term and sustainable development [1] Summary by Relevant Sections - The employee stock ownership plan involves the repurchase of up to 14 million A-shares, accounting for approximately 0.21% of the company's total share capital as of the announcement date [1] - The repurchase price is set at 30.95 yuan per share, with the final number of shares held under the plan to be determined based on actual execution [1] - The total number of employees participating in the plan is expected to be no more than 1,316 (excluding reserved shares), with a maximum of 9 individuals from the board (excluding independent directors), supervisors, and senior management [1]

Core Viewpoint - Heng Rui Medicine (01276) has announced a 2025 A-share employee stock ownership plan aimed at establishing a profit-sharing mechanism among the company, shareholders, and employees to enhance employee motivation, creativity, cohesion, and overall company competitiveness, promoting long-term and sustainable development [1] Summary by Relevant Sections - Employee Stock Ownership Plan Details - The plan involves the acquisition of up to 14 million A-shares (including reserved shares), accounting for approximately 0.21% of the company's total share capital as of the announcement date [1] - The acquisition price is set at 30.95 yuan per share, with the final number of shares held under the plan to be determined based on actual execution [1] - Participation and Eligibility - The total number of employees participating in the plan is expected to be no more than 1,316 (excluding reserved shares) [1] - Among the participants, the number of company directors (excluding independent directors), supervisors, and senior management is limited to no more than 9 (excluding reserved shares), with the final number of participants and subscription details to be confirmed based on actual employee contributions [1]

Core Insights - The innovative drug HRS-1893 has achieved a significant breakthrough with a licensing agreement between Heng Rui Medicine and Braveheart Bio, with a potential total transaction value of nearly 8 billion RMB [1][5] - The collaboration highlights the international recognition of China's innovative drug research and the focus on Southeast University's organ-on-a-chip technology [1][5] Group 1: Drug Development and Mechanism - HRS-1893 is designed to treat obstructive hypertrophic cardiomyopathy and functions as a selective inhibitor of cardiac myosin [3] - The drug's development involved collaboration with Professor Gu Zhongze's team at Southeast University, utilizing organ-on-a-chip technology for cell activity screening [3][7] Group 2: Clinical Trials and Licensing Agreement - HRS-1893 received approval for clinical trials in May 2023, marking it as the first new drug in China to use organ-on-a-chip data for such approval [5] - Braveheart Bio will have exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding certain regions in China, with Heng Rui Medicine set to receive an upfront payment of $7.5 million and potential milestone payments totaling up to $1.013 billion [5][8] Group 3: Technological Advancements and Future Plans - The organ-on-a-chip team at Southeast University has made significant advancements in key technologies over the past decade, achieving breakthroughs in high-precision 3D printing and functional biomaterials [7] - Future plans include further technological innovation and collaboration with more pharmaceutical companies to create new pathways for drug development and precision medicine [8]

证券简称：恒瑞医药 证券代码：600276 江苏恒瑞医药股份有限公司 2025 年 A 股员工持股计划 2025 年 9 月 声明 本公司及全体董事保证本员工持股计划及其摘要不存在虚假记载、误导性陈 述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 1 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 1、《江苏恒瑞医药股份有限公司 2025 年 A 股员工持股计划》系江苏恒瑞医 药股份有限公司依据《中华人民共和国公司法》《中华人民共和国证券法》《关 于上市公司实施员工持股计划试点的指导意见》《上海证券交易所上市公司自律 监管指引第 1 号——规范运作》等法律、行政法规、规章、规范性文件以及《江 苏恒瑞医药股份有限公司章程》的有关规定制定。 2、本员工持股计划遵循依法合规、自愿参与、风险自担的原则，不存在摊 派、强行分配等强制员工参加本员工持股计划的情形。 3、本员工持股计划的参加对象为公司董事（不含独立董事）、监事、高级 管理人员、公司及控股子公司核心管理人员、骨干员工和公司董事会认为应当激 励的其他员工。本员工持股计划的参加对象总人数不超过 1316 人（不含预留份 额），其中 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-144 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司苏州盛迪亚 生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局（以下简称 "国家药监局"）核准签发关于注射用 SHR-1826、阿得贝利单抗注射液、贝伐 珠单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。现将相 关情况公告如下： 野生型的晚期/转移性非鳞状非小细胞肺癌成人患者。截至目前，注射用 SHR-1826 相关项目累计研发投入约 8,809 万元。 阿得贝利单抗注射液是公司自主研发的人源化抗 PD-L1 单克隆抗体，能通过 特异性结合 PD-L1 分子从而阻断导致肿瘤免疫耐受的 PD-1/PD-L1 通路，重新激 活免疫系统的抗肿瘤活性，从而达到治疗肿瘤的目的。公司阿得贝利单抗注射液 （商品名：艾瑞利）已于 2023 年 3 月获批上市，获批的适应症为与卡铂 ...

Core Points - The Medical Health R Index (480016) closed at 8278.77 points, down 0.33%, with a trading volume of 31.765 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 18 stocks rose while 31 fell, with Yirui Technology leading the gainers at a 4.4% increase and Zexin Pharmaceutical leading the decliners at a 5.37% decrease [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.58% and a market cap of 315.96 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 10.87% and a market cap of 458.96 billion yuan [1] - Mindray Medical (sz300760) with a weight of 8.17% and a market cap of 290.50 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.14% and a market cap of 126.08 billion yuan [1] - Other notable constituents include Pianzai Shou (sh600436), Yierfu Technology (sz300015), Kelun Pharmaceutical (sz002422), New Hope Liuhe (sz002001), Fosun Pharma (sh600196), and East China Pharmaceutical (sz000963) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 1.638 billion yuan, while retail investors saw a net inflow of 1.098 billion yuan [1] - Notable capital flows include: - Kailai Ying (002821) with a main fund net inflow of 101 million yuan [2] - Mindray Medical (300760) with a main fund net inflow of approximately 90.77 million yuan [2] - Yuyue Medical (002223) with a main fund net inflow of 24.60 million yuan [2]

本次会议是否有否决议案：无 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-143 一、 会议召开和出席情况 江苏恒瑞医药股份有限公司 2025年第一次临时股东会决议公告 (一)股东会召开的时间：2025 年 9 月 16 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 1、出席会议的股东和代理人人数 | 4,505 | | --- | --- | | 股股东人数 其中：A | 4,504 | | 境外上市外资股股东人数（H 股） | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 3,068,160,282 | | 其中：A 股股东持有股份总数 | 2,900,683,191 | | 境外上市外资股股东持有股份总数（H 股） | 167,477,091 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 46.2869 | | 其中：A 股股东持股占股份总数的比例（%） | 43.7603 | | 境外上市外资股股东持股 ...

www.grandall.com.cn 中国江苏省南京市汉中门大街 309 号 B 座 5、7-8 层（210036） 5、7-8F/Block B, 309# Hanzhongmen Street, Nanjing, China Tel: 86-25-89660900 Fax: 86-25-89660966 国浩律师（南京）事务所 关于 江苏恒瑞医药股份有限公司 2025 年第一次临时股东会的 法律意见书 致：江苏恒瑞医药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）、《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》(以下简称"《监管指引第 1 号》")及《江苏恒瑞医药股份有限公 司章程》（以下简称"《公司章程》"）的规定，国浩律师（南京）事务所（以 下简称"本所"）接受江苏恒瑞医药股份有限公司（以下简称"公司"）的委托， 指派刘向明律师、张秋子律师（以下简称"本所律师"）出席公司 2025 年第一次 临时股东会（以下简称"本次股东会"或"本次会议"），对本次股东 ...

Core Insights - The company, Heng Rui Medicine, announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have received approval from the National Medical Products Administration for clinical trials of SHR-1826, Adebali monoclonal antibody injection, and Bevacizumab injection [1] Group 1 - The clinical trials will focus on the safety, tolerability, and efficacy of SHR-1826 in combination with other anti-tumor treatments for patients with solid tumors [1] - The trials will be multi-center and open-label, categorized as Phase I/II [1]